Changeflow GovPing Healthcare & Life Sciences Taladegib Patent Grant for Pulmonary Fibrosis T...
Routine Notice Added Final

Taladegib Patent Grant for Pulmonary Fibrosis Treatment

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

The USPTO granted patent US12605379B2 to Endeavor BioMedicines, Inc. covering methods of treating pulmonary fibrosis using taladegib. The patent includes 29 claims and covers CPC classifications A61K 31/502 and A61P 11/00. The filing date was September 12, 2025.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO issued patent grant US12605379B2 to Endeavor BioMedicines, Inc. for methods of improving lung function through administration of taladegib to subjects with pulmonary fibrosis. The patent covers pharmaceutical composition claims under CPC classification A61K 31/502. Pharmaceutical and biotechnology companies developing or commercializing hedgehog pathway inhibitors for respiratory indications should review this patent to assess potential freedom-to-operate implications for their programs.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Methods of improving lung function

Grant US12605379B2 Kind: B2 Apr 21, 2026

Assignee

Endeavor BioMedicines, Inc.

Inventors

Miguel de los Rios, John Hood, Anita J. DiFrancesco, Luis A. Dellamary, Paul A. Frohna

Abstract

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.

CPC Classifications

A61K 31/502 A61P 11/00

Filing Date

2025-09-12

Application No.

19327682

Claims

29

View original document →

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Notice
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent granting Pharmaceutical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!